Product Description
AMG 562 is a BiTE antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03571828)
Mechanisms of Action: CD19 Inhibitor, CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Follicular Lymphoma|Mantle-Cell Lymphoma|Diffuse Large B-Cell Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03571828 |
NCT03571828 | P1 |
Terminated |
Follicular Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma |
2022-01-12 |
20% |
2024-03-23 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/21/2019 |
News Article |
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market 2019 |